Description
IMD-0560 is a novel IκB kinase β inhibitor.
Product information
CAS Number: 439144-66-8
Molecular Weight: 428.12
Formula: C15H8BrF6NO2
Chemical Name: N-[2,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide
Smiles: OC1C=CC(Br)=CC=1C(=O)NC1C=C(C=CC=1C(F)(F)F)C(F)(F)F
InChiKey: SVGRIJCSKWXOPA-UHFFFAOYSA-N
InChi: InChI=1S/C15H8BrF6NO2/c16-8-2-4-12(24)9(6-8)13(25)23-11-5-7(14(17,18)19)1-3-10(11)15(20,21)22/h1-6,24H,(H,23,25)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
Pretreatment with IMD-0560 inhibits both IκBα degradation and p65 phosphorylation induced by TNFα. IMD-0560 also suppresses TNFα-induced transcriptional activity. Pretreatment with IMD-0560 strongly inhibits TNFα-induced cell invasion. Pretreatment with IMD-0560 suppresses MMP-9 activity by inhibiting MMP-9 expression.
In Vivo:
The tumor size is reduced in the IMD-0560-treated groups in a dose-dependent manner, and no tumor is detected in some mice treated with 5 mg/kg IMD-0560. Zygoma destruction is significantly suppressed in the IMD-0560-treated groups compare to the control groups. Although the tumor size in the 5 mg/kg IMD-0560-treated group is smaller than that of the 3 mg/kg IMD-0560-treated group, the inhibitory effect of each treatment on zygoma destruction is similar.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.